Free Trial

Encompass Health (EHC) Financials

Encompass Health logo
$119.47 -1.54 (-1.28%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$119.46 -0.01 (-0.01%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Encompass Health

Annual Income Statements for Encompass Health

This table shows Encompass Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
456 352 271 412 284 359 375 271 248 182
Consolidated Net Income / (Loss)
597 463 366 517 369 446 292 271 248 183
Net Income / (Loss) Continuing Operations
599 475 351 403 278 446 374 351 318 254
Total Pre-Tax Income
750 607 451 505 353 562 493 496 482 396
Total Operating Income
865 732 630 659 528 693 630 649 649 547
Total Gross Profit
2,415 2,145 1,901 1,829 1,601 1,950 1,923 1,759 1,657 1,445
Total Revenue
5,373 4,801 4,349 4,015 3,566 4,605 4,277 3,914 3,643 3,163
Operating Revenue
5,373 4,801 4,349 4,015 3,566 4,605 4,277 3,914 3,643 3,163
Total Cost of Revenue
2,958 2,656 2,448 2,186 1,965 2,655 2,354 2,155 1,986 1,718
Operating Cost of Revenue
2,958 2,656 2,448 2,186 1,965 2,655 2,354 2,155 1,986 1,671
Total Operating Expenses
1,550 1,413 1,270 1,169 1,074 1,257 1,294 1,110 1,008 898
Selling, General & Admin Expense
1,251 1,139 1,027 950 868 1,039 964 853 764 697
Depreciation Expense
300 274 244 220 203 219 200 184 173 140
Total Other Income / (Expense), net
-115 -125 -179 -154 -175 -130 -136 -153 -167 -151
Interest Expense
138 144 177 165 186 167 147 165 180 165
Interest & Investment Income
3.00 3.20 2.90 3.40 2.90 6.70 8.70 8.00 9.80 8.70
Other Income / (Expense), net
20 16 -5.20 7.50 8.40 31 2.20 4.10 2.90 5.50
Income Tax Expense
150 132 100 102 75 116 119 146 164 142
Net Income / (Loss) Discontinued Operations
-2.80 -12 15 114 91 -0.60 1.10 -0.40 0.00 -0.90
Net Income / (Loss) Attributable to Noncontrolling Interest
141 111 95 105 85 87 - - - -
Basic Earnings per Share
$4.53 $3.51 $2.72 $4.15 $2.87 $3.65 $2.98 $2.88 $2.77 $2.02
Weighted Average Basic Shares Outstanding
99.90M 99.50M 99.20M 99M 98.60M 98M 97.90M 93.70M 89.10M 89.40M
Diluted Earnings per Share
$4.46 $3.47 $2.70 $4.11 $2.85 $3.61 $2.93 $2.84 $2.59 $1.91
Weighted Average Diluted Shares Outstanding
102.20M 101.30M 100.40M 100.20M 99.80M 99.40M 99.80M 99.30M 99.50M 101M
Weighted Average Basic & Diluted Shares Outstanding
100.71M 100.14M 99.73M 99.44M 99.27M 98.43M 98.10M 99.30M 89.05M 89.78M
Cash Dividends to Common per Share
$0.64 $0.60 $0.86 $1.12 $1.12 $1.10 $1.04 $0.98 $0.94 $0.88

Quarterly Income Statements for Encompass Health

This table shows Encompass Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
152 121 108 114 113 88 85 91 88 89 45
Consolidated Net Income / (Loss)
197 164 147 147 139 119 113 117 113 139 45
Net Income / (Loss) Continuing Operations
197 164 148 148 140 128 115 118 114 119 86
Total Pre-Tax Income
239 201 184 186 178 165 145 151 146 151 107
Total Operating Income
267 232 209 216 208 190 179 184 179 180 148
Total Gross Profit
678 634 605 587 590 557 534 537 518 510 472
Total Revenue
1,455 1,405 1,351 1,301 1,316 1,247 1,207 1,187 1,160 1,137 1,090
Operating Revenue
1,455 1,405 1,351 1,301 1,316 1,247 1,207 1,187 1,160 1,137 1,090
Total Cost of Revenue
777 772 747 715 726 690 673 651 643 628 618
Operating Cost of Revenue
777 772 747 715 726 690 673 651 643 628 618
Total Operating Expenses
411 401 395 371 383 367 355 353 339 330 323
Selling, General & Admin Expense
332 323 317 298 313 297 287 280 275 267 261
Depreciation Expense
79 78 78 73 70 70 67 73 64 63 62
Total Other Income / (Expense), net
-28 -31 -25 -30 -29 -25 -34 -33 -32 -29 -41
Interest Expense
32 33 35 34 35 35 36 36 36 38 38
Interest & Investment Income
0.90 0.20 0.70 1.40 0.70 0.90 1.00 0.90 0.40 0.30 0.70
Other Income / (Expense), net
2.50 2.10 9.30 3.30 5.40 8.90 0.50 2.70 3.60 8.40 -3.60
Income Tax Expense
42 38 36 38 38 37 30 33 32 32 22
Net Income / (Loss) Discontinued Operations
-0.50 0.40 -0.70 -1.20 -1.30 -8.50 -1.30 -1.20 -1.00 -1.50 -19
Net Income / (Loss) Attributable to Noncontrolling Interest
45 43 39 32 26 32 28 26 26 - -
Basic Earnings per Share
$1.50 $1.20 $1.08 $1.13 $1.12 $0.88 $0.85 $0.91 $0.88 $0.90 $0.45
Weighted Average Basic Shares Outstanding
100.50M 99.90M 99.90M 99.90M 99.80M 99.50M 99.50M 99.50M 99.40M 99.20M 99.20M
Diluted Earnings per Share
$1.48 $1.18 $1.06 $1.12 $1.10 $0.88 $0.84 $0.90 $0.87 $0.90 $0.45
Weighted Average Diluted Shares Outstanding
102.10M 102.20M 102.10M 102M 102.20M 101.30M 101.40M 101.10M 100.90M 100.40M 100.50M
Weighted Average Basic & Diluted Shares Outstanding
100.80M 100.71M 100.75M 100.63M 100.69M 100.14M 100.24M 100.23M 100.24M 99.73M 99.79M
Cash Dividends to Common per Share
$0.17 - $0.17 $0.15 $0.15 $0.38 $0.15 $0.15 $0.15 $0.44 $0.15

Annual Cash Flow Statements for Encompass Health

This table details how cash moves in and out of Encompass Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
19 51 -67 -191 151 26 17 15 -6.10 -5.10
Net Cash From Operating Activities
1,003 851 706 716 705 635 762 658 640 502
Net Cash From Continuing Operating Activities
1,003 851 706 716 705 640 762 658 640 502
Net Income / (Loss) Continuing Operations
599 475 351 403 278 446 374 351 318 254
Consolidated Net Income / (Loss)
597 463 366 517 369 446 375 350 318 253
Net Income / (Loss) Discontinued Operations
-2.80 -12 15 114 91 -0.60 1.10 0.40 0.00 -0.90
Depreciation Expense
300 274 244 220 203 219 200 184 173 140
Amortization Expense
9.70 9.50 9.70 7.80 7.20 4.50 4.00 8.70 14 14
Non-Cash Adjustments To Reconcile Net Income
62 38 104 178 74 110 148 62 33 97
Changes in Operating Assets and Liabilities, net
33 54 -2.50 -93 143 -140 37 53 103 -2.80
Net Cash From Investing Activities
-653 -603 -627 -666 -408 -657 -425 -283 -230 -1,130
Net Cash From Continuing Investing Activities
-653 -603 -624 -547 -405 -657 -425 -283 -230 -1,130
Purchase of Property, Plant & Equipment
-643 -583 -584 -546 -401 -385 -271 -245 -203 -157
Purchase of Investments
-23 -23 -35 -9.00 -8.70 -33 -13 -8.50 -1.30 -7.10
Sale and/or Maturity of Investments
19 7.40 0.00 - 13 18 12 4.20 0.10 13
Other Investing Activities, net
-7.20 -4.10 -4.20 7.60 -3.80 -6.50 -2.70 8.80 -1.70 1.60
Net Cash From Discontinued Investing Activities
0.00 0.00 -3.50 -119 -3.00 - - - 0.10 0.50
Net Cash From Financing Activities
-331 -197 -146 -240 -146 48 -321 -360 -416 623
Net Cash From Continuing Financing Activities
-331 -197 -661 -230 -134 48 -321 -360 -416 623
Repayment of Debt
-335 -162 -755 -315 -1,126 -1,169 -429 -480 -529 -1,376
Repurchase of Common Equity
-31 0.00 0.00 - -6.10 -46 0.00 -38 -66 -45
Payment of Dividends
-188 -175 -196 -213 -345 -351 -241 -143 -149 -132
Issuance of Debt
95 80 252 300 1,323 1,635 344 274 335 2,190
Issuance of Common Equity
140 68 64 57 35 16 13 21 3.50 3.00
Other Financing Activities, net
-12 -8.20 -27 -59 -15 -36 -8.30 6.80 -12 -17
Net Cash From Discontinued Financing Activities
0.00 0.00 515 -10 -12 - - - - -
Cash Interest Paid
147 148 178 168 168 156 150 151 164 121
Cash Income Taxes Paid
165 109 51 131 34 104 115 96 33 17

Quarterly Cash Flow Statements for Encompass Health

This table details how cash moves in and out of Encompass Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-0.30 -76 17 9.40 69 -37 -13 35 66 -51 -153
Net Cash From Operating Activities
289 279 268 217 239 201 215 207 228 172 70
Net Cash From Continuing Operating Activities
289 279 268 217 239 201 215 207 228 172 146
Net Income / (Loss) Continuing Operations
197 164 148 148 140 128 115 118 114 119 86
Consolidated Net Income / (Loss)
197 164 147 147 139 119 113 117 113 118 67
Net Income / (Loss) Discontinued Operations
-0.50 0.40 -0.70 -1.20 -1.30 -8.50 -1.30 -1.20 -1.00 -1.50 -19
Depreciation Expense
79 78 78 73 70 70 67 73 64 63 62
Non-Cash Adjustments To Reconcile Net Income
11 16 11 11 24 -4.40 19 16 7.80 -1.50 70
Changes in Operating Assets and Liabilities, net
1.30 11 30 -14 4.90 -1.80 14 -0.20 42 -18 -71
Net Cash From Investing Activities
-159 -204 -162 -158 -130 -208 -162 -129 -104 -206 -174
Net Cash From Continuing Investing Activities
-159 -204 -162 -158 -130 -208 -162 -129 -104 -207 -174
Purchase of Property, Plant & Equipment
-163 -199 -148 -157 -139 -212 -150 -122 -100 -209 -149
Sale and/or Maturity of Investments
11 1.00 0.90 1.00 16 0.40 6.00 0.80 0.20 - -
Other Investing Activities, net
-6.40 -3.50 5.10 -2.50 -6.30 5.10 2.60 -7.40 -4.40 13 0.20
Net Cash From Financing Activities
-130 -151 -90 -50 -41 -30 -66 -44 -58 -17 -49
Net Cash From Continuing Financing Activities
-130 -151 -90 -50 -41 -30 -66 -44 -58 -16 4.70
Repayment of Debt
-88 -134 -140 -5.00 -56 -42 9.60 -80 -50 -34 -24
Repurchase of Common Equity
-32 -7.50 -6.80 - - - - - - - -
Payment of Dividends
-51 -57 -48 -43 -41 -38 -48 -43 -47 -43 -50
Issuance of Debt
60 30 15 - 50 - - 50 30 72 50
Issuance of Common Equity
0.00 0.70 106 15 18 14 8.40 29 17 9.00 20
Other Financing Activities, net
-20 16 -16 - -12 36 -36 - -7.70 -19 9.40

Annual Balance Sheets for Encompass Health

This table presents Encompass Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
6,535 6,102 5,637 6,865 6,446 6,081 5,175 2,089 4,682 4,606
Total Current Assets
887 842 717 921 949 756 662 117 655 599
Cash & Equivalents
85 69 22 49 224 95 69 54 41 62
Restricted Cash
38 35 32 63 65 57 - 62 61 46
Accounts Receivable
599 612 537 516 573 506 468 - 444 411
Prepaid Expenses
42 35 35 115 86 98 66 - 109 81
Other Current Assets
123 92 92 - - - 59 - - -
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 1,635 0.00 1,392 1,310
Total Noncurrent Assets
5,648 5,261 4,919 5,944 5,497 5,325 2,878 1,973 2,636 2,697
Goodwill
1,284 1,281 1,263 1,237 2,319 2,305 2,101 1,973 1,927 1,890
Intangible Assets
298 278 282 158 431 476 443 - 411 419
Other Noncurrent Operating Assets
4,066 3,701 3,374 3,005 2,747 2,541 291 - 221 197
Total Liabilities & Shareholders' Equity
6,535 6,102 5,637 6,865 6,446 6,081 5,175 0.00 4,682 4,606
Total Liabilities
3,686 3,805 3,775 4,466 4,444 4,148 3,356 0.00 3,615 3,706
Total Current Liabilities
841 656 576 749 717 721 673 0.00 476 426
Short-Term Debt
139 25 25 38 38 39 36 - 37 37
Accounts Payable
171 170 133 134 115 95 90 - 68 62
Current Employee Benefit Liabilities
228 208 168 199 254 211 188 - 147 126
Other Current Liabilities
265 212 207 201 263 344 334 - 197 172
Other Current Nonoperating Liabilities
39 43 43 177 47 32 24 - 26 30
Total Noncurrent Liabilities
2,845 3,149 3,199 3,717 3,727 3,427 2,684 0.00 3,139 3,279
Long-Term Debt
2,359 2,688 2,742 3,241 3,251 3,023 2,479 - 2,979 3,135
Asset Retirement Reserve & Litigation Obligation
139 132 129 124 121 117 120 - 110 102
Noncurrent Deferred & Payable Income Tax Liabilities
105 87 83 23 52 0.00 - - - -
Other Noncurrent Operating Liabilities
242 242 245 229 303 287 86 - 50 43
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Redeemable Noncontrolling Interest
57 42 36 42 32 240 262 - 138 121
Total Equity & Noncontrolling Interests
2,793 2,255 1,826 2,357 1,970 1,693 1,557 0.00 929 779
Total Preferred & Common Equity
2,067 1,648 1,310 1,911 1,588 1,352 1,277 0.00 736 611
Total Common Equity
2,067 1,648 1,310 1,911 1,588 1,352 1,277 0.00 736 611
Common Stock
1,848 1,788 1,731 2,291 2,328 2,371 2,590 - 2,800 2,836
Retained Earnings
797 407 116 142 -242 -527 -885 - -1,448 -1,696
Treasury Stock
-578 -547 -537 -521 -497 -492 -428 - -615 -527
Noncontrolling Interest
726 608 516 446 382 341 280 - 193 168

Quarterly Balance Sheets for Encompass Health

This table presents Encompass Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
6,641 6,458 6,389 6,231 5,964 5,861 5,747 5,476
Total Current Assets
911 934 938 930 814 824 762 734
Cash & Equivalents
96 148 154 134 100 118 85 60
Restricted Cash
27 51 28 38 42 37 34 44
Accounts Receivable
623 576 590 619 536 532 515 500
Other Current Assets
165 159 166 138 137 138 128 130
Plant, Property, & Equipment, net
3,724 3,524 3,439 3,370 3,186 0.00 2,988 2,807
Total Noncurrent Assets
2,007 2,001 2,012 1,931 1,964 5,037 1,997 1,935
Goodwill
1,284 1,284 1,284 1,281 1,281 1,271 1,271 1,247
Intangible Assets
295 296 303 272 276 278 287 285
Other Noncurrent Operating Assets
428 421 425 378 407 3,488 439 402
Total Liabilities & Shareholders' Equity
6,641 6,458 6,389 6,231 5,964 5,861 5,747 5,476
Total Liabilities
3,704 3,733 3,859 3,828 3,775 3,804 3,784 3,728
Total Current Liabilities
856 897 695 680 639 655 592 605
Short-Term Debt
139 233 33 26 24 23 26 26
Accounts Payable
159 170 164 166 165 156 141 134
Other Current Liabilities
558 494 498 489 450 442 393 444
Total Noncurrent Liabilities
2,848 2,835 3,164 3,148 3,136 3,149 3,192 3,123
Long-Term Debt
2,333 2,345 2,684 2,683 2,693 2,698 2,723 2,719
Noncurrent Deferred & Payable Income Tax Liabilities
114 97 91 94 80 83 87 47
Other Noncurrent Operating Liabilities
401 394 389 372 363 368 383 357
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
56 57 49 41 42 39 38 38
Total Equity & Noncontrolling Interests
2,882 2,669 2,481 2,362 2,148 2,018 1,926 1,710
Total Preferred & Common Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest
2,882 2,669 2,481 2,362 2,148 2,018 1,926 1,710

Annual Metrics And Ratios for Encompass Health

This table displays calculated financial ratios and metrics derived from Encompass Health's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - -
Revenue Growth
11.91% 10.41% 8.31% 12.58% -22.56% 7.66% 9.28% 15.17% 31.46%
EBITDA Growth
15.81% 17.37% -1.79% 19.85% -21.14% 13.25% -1.24% 18.68% 14.09%
EBIT Growth
18.34% 19.60% -6.28% 24.42% -25.86% 14.43% -3.32% 18.02% 10.75%
NOPAT Growth
20.75% 16.77% -6.85% 26.55% -24.35% 15.06% 4.18% 22.13% 5.08%
Net Income Growth
28.86% 26.54% -29.25% 40.24% -17.27% 52.51% 7.82% 35.23% -17.52%
EPS Growth
28.53% 28.52% -34.31% 40.24% -17.27% 23.21% 3.17% 35.60% -16.59%
Operating Cash Flow Growth
17.87% 20.54% -1.40% 1.58% 10.92% -16.67% 15.81% 27.53% 12.83%
Free Cash Flow Firm Growth
55.41% 3,648.60% -100.47% 497.54% 749.69% 97.96% -173.70% 150.18% -70.65%
Invested Capital Growth
6.35% 7.14% 12.06% -18.36% 3.54% 13.69% 117.39% 0.34% 41.76%
Revenue Q/Q Growth
3.03% 2.33% 17.62% 9.54% -22.71% 1.96% 2.08% 0.17% 9.18%
EBITDA Q/Q Growth
4.66% 2.69% 18.56% 3.65% -13.60% 7.52% -5.61% 2.90% 11.06%
EBIT Q/Q Growth
4.19% 1.45% 24.06% -1.58% -14.19% 8.43% -8.67% 1.15% 8.25%
NOPAT Q/Q Growth
6.45% 0.92% 20.70% 0.21% -14.19% 10.99% -10.48% 3.98% 3.04%
Net Income Q/Q Growth
8.18% -4.14% 6.83% 18.76% -24.66% 39.66% -9.22% 6.68% -8.27%
EPS Q/Q Growth
5.44% -2.53% -1.82% 18.76% -24.66% -12.38% -14.33% 7.92% 3.24%
Operating Cash Flow Q/Q Growth
8.41% 3.50% 7.36% -17.88% 10.01% 6.22% 3.67% 1.11% 14.51%
Free Cash Flow Firm Q/Q Growth
21.69% 26.37% -100.51% 651.35% -60.62% 88.73% -585.24% 166.98% -61.66%
Invested Capital Q/Q Growth
3.10% 3.85% 5.22% -22.69% 0.99% -4.99% -0.37% 1.27% 36.46%
Profitability Metrics
- - - - - - - - -
Gross Margin
44.94% 44.67% 43.71% 45.55% 44.90% 42.34% 44.97% 45.48% 45.68%
EBITDA Margin
22.22% 21.47% 20.20% 22.27% 20.92% 20.55% 19.53% 23.01% 22.33%
Operating Margin
16.09% 15.24% 14.49% 16.42% 14.79% 15.04% 14.72% 17.81% 17.28%
EBIT Margin
16.46% 15.57% 14.37% 16.61% 15.03% 15.70% 14.77% 17.89% 17.46%
Profit (Net Income) Margin
11.10% 9.64% 8.41% 12.88% 10.34% 9.68% 6.83% 6.80% 5.79%
Tax Burden Percent
79.59% 76.25% 81.17% 102.42% 104.51% 79.28% 59.27% 51.37% 46.28%
Interest Burden Percent
84.74% 81.23% 72.13% 75.72% 65.84% 77.77% 78.06% 73.96% 71.64%
Effective Tax Rate
20.04% 21.77% 22.21% 20.18% 21.17% 20.61% 24.11% 34.00% 35.87%
Return on Invested Capital (ROIC)
13.54% 11.97% 11.22% 11.48% 8.38% 12.00% 15.26% 10.70% 10.29%
ROIC Less NNEP Spread (ROIC-NNEP)
9.80% 7.92% 5.67% 11.10% 6.81% 8.16% 6.91% 4.72% 3.74%
Return on Net Nonoperating Assets (RNNOA)
9.64% 10.30% 5.95% 12.02% 10.37% 11.77% 16.88% 14.47% 11.27%
Return on Equity (ROE)
23.19% 22.26% 17.17% 23.50% 18.75% 23.77% 32.14% 25.17% 21.57%
Cash Return on Invested Capital (CROIC)
7.38% 5.07% -0.16% 31.70% 4.90% -0.82% -58.71% 10.36% -24.25%
Operating Return on Assets (OROA)
14.00% 12.74% 10.00% 10.02% 8.56% 12.85% 17.39% 14.03% 13.81%
Return on Assets (ROA)
9.44% 7.89% 5.85% 7.77% 5.89% 7.92% 8.05% 5.33% 4.58%
Return on Common Equity (ROCE)
16.73% 15.83% 12.98% 18.69% 14.01% 16.66% 22.56% 17.24% 13.78%
Return on Equity Simple (ROE_SIMPLE)
28.86% 28.10% 27.92% 27.06% 23.22% 32.97% 22.90% 33.65% 29.95%
Net Operating Profit after Tax (NOPAT)
691 572 490 526 416 550 478 428 351
NOPAT Margin
12.87% 11.92% 11.27% 13.11% 11.66% 11.94% 11.17% 11.75% 11.08%
Net Nonoperating Expense Percent (NNEP)
3.74% 4.05% 5.55% 0.38% 1.57% 3.84% 8.35% 5.99% 6.55%
Return On Investment Capital (ROIC_SIMPLE)
13.07% 11.52% 10.67% - - - - - -
Cost of Revenue to Revenue
55.06% 55.33% 56.29% 54.45% 55.10% 57.66% 55.03% 54.52% 54.32%
SG&A Expenses to Revenue
23.28% 23.73% 23.61% 23.65% 24.33% 22.55% 22.54% 20.97% 22.04%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
28.85% 29.43% 29.21% 29.12% 30.10% 27.30% 30.25% 27.67% 28.40%
Earnings before Interest and Taxes (EBIT)
885 748 625 667 536 723 632 652 552
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,194 1,031 878 894 746 946 836 838 706
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
4.49 4.03 4.48 3.30 4.96 4.75 4.42 4.48 4.53
Price to Tangible Book Value (P/TBV)
19.14 75.45 0.00 12.23 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.73 1.38 1.35 1.57 2.21 1.40 1.32 0.91 0.88
Price to Earnings (P/E)
20.38 18.86 21.66 15.31 27.70 17.92 15.04 13.33 15.26
Dividend Yield
0.67% 0.91% 1.37% 1.77% 1.41% 1.69% 1.82% 2.56% 2.91%
Earnings Yield
4.91% 5.30% 4.62% 6.53% 3.61% 5.58% 6.65% 7.50% 6.55%
Enterprise Value to Invested Capital (EV/IC)
2.36 2.00 1.98 2.42 2.24 2.03 2.01 1.63 1.53
Enterprise Value to Revenue (EV/Rev)
2.32 2.06 2.10 2.48 3.16 2.15 2.02 1.80 1.94
Enterprise Value to EBITDA (EV/EBITDA)
10.42 9.60 10.40 11.14 15.12 10.48 10.33 7.81 8.67
Enterprise Value to EBIT (EV/EBIT)
14.07 13.24 14.61 14.94 21.05 13.72 13.66 10.05 11.09
Enterprise Value to NOPAT (EV/NOPAT)
18.00 17.29 18.63 18.93 27.13 18.04 18.07 15.29 17.46
Enterprise Value to Operating Cash Flow (EV/OCF)
12.41 11.63 12.94 13.92 16.01 15.61 11.32 10.23 12.20
Enterprise Value to Free Cash Flow (EV/FCFF)
33.01 40.80 0.00 6.86 46.40 0.00 0.00 15.79 0.00
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.88 1.18 1.49 1.37 1.64 1.58 1.38 2.83 3.52
Long-Term Debt to Equity
0.83 1.17 1.47 1.35 1.62 1.56 1.36 2.79 3.48
Financial Leverage
0.98 1.30 1.05 1.08 1.52 1.44 2.44 3.07 3.01
Leverage Ratio
2.46 2.82 2.93 3.02 3.18 3.00 3.99 4.72 4.71
Compound Leverage Factor
2.08 2.29 2.12 2.29 2.10 2.33 3.12 3.49 3.37
Debt to Total Capital
46.71% 54.15% 59.78% 57.74% 62.17% 61.31% 58.03% 73.87% 77.89%
Short-Term Debt to Total Capital
2.59% 0.50% 0.54% 0.67% 0.72% 0.79% 0.83% 0.91% 0.90%
Long-Term Debt to Total Capital
44.12% 53.65% 59.23% 57.08% 61.44% 60.52% 57.20% 72.96% 76.98%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
14.63% 12.97% 11.92% 8.59% 7.82% 11.62% 12.51% 8.11% 7.10%
Common Equity to Total Capital
38.66% 32.89% 28.31% 33.66% 30.02% 27.07% 29.46% 18.02% 15.02%
Debt to EBITDA
2.09 2.63 3.15 3.67 4.41 3.24 3.01 3.60 4.49
Net Debt to EBITDA
1.99 2.53 3.09 3.54 4.02 3.08 2.93 3.48 4.34
Long-Term Debt to EBITDA
1.98 2.61 3.12 3.62 4.36 3.20 2.97 3.55 4.44
Debt to NOPAT
3.61 4.74 5.64 6.23 7.91 5.57 5.26 7.04 9.05
Net Debt to NOPAT
3.44 4.56 5.54 6.02 7.21 5.29 5.12 6.81 8.74
Long-Term Debt to NOPAT
3.41 4.70 5.59 6.16 7.82 5.50 5.19 6.96 8.94
Altman Z-Score
2.96 2.37 2.13 1.81 1.88 1.97 2.00 1.40 1.06
Noncontrolling Interest Sharing Ratio
27.82% 28.88% 24.40% 20.48% 25.27% 29.92% 29.80% 31.52% 36.12%
Liquidity Ratios
- - - - - - - - -
Current Ratio
1.05 1.28 1.25 1.23 1.32 1.05 0.98 1.38 1.40
Quick Ratio
0.81 1.04 0.97 0.75 1.11 0.83 0.80 1.02 1.11
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
377 243 -6.84 1,453 243 -37 -1,838 414 -826
Operating Cash Flow to CapEx
156.08% 145.91% 120.84% 131.17% 175.69% 164.84% 281.85% 357.65% 329.18%
Free Cash Flow to Firm to Interest Expense
2.73 1.69 -0.04 8.79 1.31 -0.22 -12.48 2.31 -5.00
Operating Cash Flow to Interest Expense
7.27 5.93 3.99 4.33 3.79 3.80 5.18 3.57 3.04
Operating Cash Flow Less CapEx to Interest Expense
2.61 1.87 0.69 1.03 1.63 1.49 3.34 2.57 2.11
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.85 0.82 0.70 0.60 0.57 0.82 1.18 0.78 0.79
Accounts Receivable Turnover
8.88 8.36 8.26 7.38 6.61 9.46 0.00 8.53 8.62
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.70 2.72
Accounts Payable Turnover
17.35 17.54 18.34 17.56 18.75 28.77 0.00 30.58 29.88
Days Sales Outstanding (DSO)
41.11 43.65 44.18 49.48 55.21 38.59 0.00 42.80 42.33
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
21.04 20.81 19.90 20.79 19.46 12.69 0.00 11.94 12.22
Cash Conversion Cycle (CCC)
20.07 22.84 24.28 28.70 35.75 25.90 0.00 30.86 30.12
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
5,263 4,948 4,618 4,121 5,048 4,876 4,288 4,008 3,994
Invested Capital Turnover
1.05 1.00 1.00 0.88 0.72 1.01 1.37 0.91 0.93
Increase / (Decrease) in Invested Capital
314 330 497 -927 173 587 2,316 14 1,177
Enterprise Value (EV)
12,444 9,898 9,134 9,963 11,284 9,919 8,632 6,546 6,123
Market Capitalization
9,287 6,640 5,869 6,309 7,871 6,429 5,645 3,300 2,770
Book Value per Share
$20.52 $16.44 $13.13 $19.21 $15.97 $13.71 $12.91 $8.20 $6.69
Tangible Book Value per Share
$4.82 $0.88 ($2.36) $5.19 ($11.69) ($14.50) ($12.81) ($17.85) ($18.57)
Total Capital
5,347 5,010 4,629 5,678 5,291 4,995 4,333 4,083 4,072
Total Debt
2,498 2,713 2,767 3,278 3,289 3,063 2,514 3,016 3,172
Total Long-Term Debt
2,359 2,688 2,742 3,241 3,251 3,023 2,479 2,979 3,135
Net Debt
2,375 2,608 2,714 3,166 3,000 2,910 2,445 2,915 3,064
Capital Expenditures (CapEx)
643 583 584 546 401 385 271 179 153
Debt-free, Cash-free Net Working Capital (DFCFNWC)
61 106 113 99 -20 -78 -44 115 102
Debt-free Net Working Capital (DFNWC)
185 210 167 210 270 74 25 216 209
Net Working Capital (NWC)
46 185 141 173 231 35 -10 179 172
Net Nonoperating Expense (NNE)
95 109 124 9.14 47 104 186 181 168
Net Nonoperating Obligations (NNO)
2,413 2,651 2,756 1,722 3,047 2,943 2,470 2,941 3,094
Total Depreciation and Amortization (D&A)
309 283 253 227 210 223 204 186 154
Debt-free, Cash-free Net Working Capital to Revenue
1.14% 2.21% 2.60% 2.45% -0.56% -1.70% -1.02% 3.15% 3.21%
Debt-free Net Working Capital to Revenue
3.43% 4.38% 3.83% 5.24% 7.56% 1.61% 0.59% 5.93% 6.61%
Net Working Capital to Revenue
0.85% 3.86% 3.25% 4.30% 6.49% 0.76% -0.24% 4.91% 5.45%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
$4.53 $3.51 $2.72 $3.30 $2.28 $2.91 $2.37 $2.21 $1.61
Adjusted Weighted Average Basic Shares Outstanding
99.90M 99.50M 99.20M 124.35M 123.84M 123.09M 122.96M 111.91M 112.29M
Adjusted Diluted Earnings per Share
$4.46 $3.47 $2.70 $3.27 $2.27 $2.87 $2.33 $2.06 $1.52
Adjusted Weighted Average Diluted Shares Outstanding
102.20M 101.30M 100.40M 125.85M 125.35M 124.85M 125.35M 124.97M 126.86M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
100.71M 100.14M 99.73M 124.90M 124.68M 123.63M 124.02M 111.85M 112.76M
Normalized Net Operating Profit after Tax (NOPAT)
691 572 490 526 418 550 517 428 355
Normalized NOPAT Margin
12.87% 11.92% 11.27% 13.11% 11.72% 11.94% 12.09% 11.75% 11.24%
Pre Tax Income Margin
13.95% 12.65% 10.37% 12.58% 9.90% 12.21% 11.53% 13.23% 12.51%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
6.41 5.21 3.53 4.03 2.88 4.32 4.29 3.63 3.34
NOPAT to Interest Expense
5.01 3.99 2.77 3.18 2.24 3.28 3.24 2.39 2.12
EBIT Less CapEx to Interest Expense
1.75 1.15 0.23 0.73 0.73 2.02 2.45 2.63 2.42
NOPAT Less CapEx to Interest Expense
0.35 -0.07 -0.53 -0.12 0.08 0.98 1.41 1.39 1.20
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
31.48% 37.82% 53.46% 41.24% 93.55% 78.82% 82.55% 60.06% 71.87%
Augmented Payout Ratio
36.69% 37.82% 53.46% 41.24% 95.20% 89.12% 82.55% 86.55% 96.61%

Quarterly Metrics And Ratios for Encompass Health

This table displays calculated financial ratios and metrics derived from Encompass Health's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
10.59% 12.69% 11.94% 9.61% 13.41% 9.63% 10.78% 11.73% 9.54% 134.01% 7.79%
EBITDA Growth
23.13% 16.18% 20.06% 12.58% 15.08% 6.96% 19.48% 27.31% 19.06% 103.40% 1.27%
EBIT Growth
26.59% 17.91% 21.40% 17.31% 16.85% 5.69% 24.24% 30.40% 22.28% 181.17% -13.45%
NOPAT Growth
35.28% 28.49% 18.49% 18.89% 16.70% 3.76% 20.01% 33.05% 16.49% 129.16% -10.91%
Net Income Growth
41.57% 37.87% 29.72% 25.00% 22.51% -14.38% 149.78% 64.38% 2.91% 20.22% -64.17%
EPS Growth
34.55% 34.09% 26.19% 24.44% 26.44% -2.22% 86.67% 83.67% 0.00% -3.23% -55.00%
Operating Cash Flow Growth
20.85% 38.71% 24.44% 5.18% 4.78% 16.72% 206.99% -15.49% 4.11% 39.10% -60.53%
Free Cash Flow Firm Growth
30.62% 31.44% 26.54% -124.75% -115.99% 48.54% -122.03% 599.21% 390.68% -135.94% 632.32%
Invested Capital Growth
7.04% 6.35% 7.13% 9.54% 7.55% 7.14% 8.55% -16.99% -18.00% 12.06% -17.66%
Revenue Q/Q Growth
3.59% 4.00% 3.83% -1.12% 5.55% 3.31% 1.67% 2.30% 2.03% 4.39% 2.54%
EBITDA Q/Q Growth
11.62% 5.26% 1.71% 3.04% 5.32% 8.78% -4.63% 5.32% -2.11% 21.51% 1.62%
EBIT Q/Q Growth
14.97% 7.33% -0.23% 2.82% 7.09% 10.51% -3.59% 2.41% -3.14% 29.90% 1.19%
NOPAT Q/Q Growth
16.68% 12.36% -1.79% 5.06% 10.83% 3.61% -1.45% 3.13% -1.47% 19.84% 9.25%
Net Income Q/Q Growth
19.67% 11.62% 0.41% 5.55% -5.71% 5.03% -3.24% 3.44% -18.55% 206.39% -36.33%
EPS Q/Q Growth
25.42% 11.32% -5.36% 1.82% 25.00% 4.76% -6.67% 3.45% -3.33% 100.00% -8.16%
Operating Cash Flow Q/Q Growth
3.52% 4.11% 23.18% -8.96% 18.81% -6.60% 4.11% -9.30% 32.35% 145.65% -71.34%
Free Cash Flow Firm Q/Q Growth
-1.58% 26.88% 36.47% -47.04% -30.86% 21.65% -121.40% -4.98% 422.95% -133.54% 585.04%
Invested Capital Q/Q Growth
0.46% 3.10% 0.78% 2.54% 0.68% 3.85% 3.05% 0.68% -0.56% 5.22% -21.20%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
46.60% 45.09% 44.74% 45.07% 44.86% 44.63% 44.25% 45.20% 44.61% 44.83% 43.28%
EBITDA Margin
23.96% 22.23% 21.97% 22.43% 21.52% 21.57% 20.48% 21.83% 21.21% 22.11% 18.99%
Operating Margin
18.35% 16.53% 15.48% 16.57% 15.77% 15.23% 14.86% 15.49% 15.39% 15.80% 13.62%
EBIT Margin
18.52% 16.68% 16.17% 16.82% 16.18% 15.94% 14.91% 15.72% 15.70% 16.54% 13.29%
Profit (Net Income) Margin
13.50% 11.69% 10.89% 11.26% 10.55% 9.55% 9.40% 9.87% 9.76% 12.23% 4.17%
Tax Burden Percent
82.36% 81.53% 80.03% 78.76% 77.80% 72.27% 78.21% 77.51% 77.50% 92.18% 42.31%
Interest Burden Percent
88.53% 85.92% 84.16% 84.97% 83.80% 82.90% 80.60% 81.03% 80.24% 80.22% 74.10%
Effective Tax Rate
17.44% 18.67% 19.59% 20.59% 21.47% 22.57% 20.90% 21.69% 21.82% 21.14% 20.32%
Return on Invested Capital (ROIC)
16.33% 14.15% 13.15% 13.77% 12.88% 11.84% 12.05% 10.89% 10.51% 12.40% 8.26%
ROIC Less NNEP Spread (ROIC-NNEP)
15.35% 13.18% 12.30% 12.81% 11.94% 10.80% 10.96% 9.93% 9.59% 12.28% 5.69%
Return on Net Nonoperating Assets (RNNOA)
14.04% 12.97% 12.40% 14.24% 14.13% 14.05% 14.52% 12.07% 12.35% 12.91% 8.00%
Return on Equity (ROE)
30.37% 27.12% 25.56% 28.01% 27.01% 25.88% 26.58% 22.95% 22.86% 25.31% 16.25%
Cash Return on Invested Capital (CROIC)
7.84% 7.38% 6.28% 3.76% 5.23% 5.07% 4.19% 29.24% 29.79% -0.16% 27.73%
Operating Return on Assets (OROA)
15.86% 14.19% 13.57% 13.93% 13.39% 13.04% 12.23% 11.11% 11.01% 11.51% 8.06%
Return on Assets (ROA)
11.56% 9.94% 9.14% 9.32% 8.73% 7.81% 7.71% 6.98% 6.85% 8.51% 2.53%
Return on Common Equity (ROCE)
0.00% 19.57% 0.00% 0.00% 0.00% 18.41% 0.00% 0.00% 0.00% 19.14% 0.00%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
220 189 168 171 163 147 142 144 140 142 118
NOPAT Margin
15.15% 13.45% 12.45% 13.16% 12.38% 11.79% 11.76% 12.13% 12.03% 12.46% 10.85%
Net Nonoperating Expense Percent (NNEP)
0.98% 0.98% 0.85% 0.97% 0.94% 1.03% 1.09% 0.96% 0.92% 0.12% 2.57%
Return On Investment Capital (ROIC_SIMPLE)
4.12% 3.57% - - - 2.96% - - - 3.09% -
Cost of Revenue to Revenue
53.40% 54.91% 55.26% 54.93% 55.14% 55.37% 55.75% 54.80% 55.39% 55.17% 56.72%
SG&A Expenses to Revenue
22.81% 23.00% 23.46% 22.90% 23.75% 23.78% 23.81% 23.60% 23.71% 23.46% 23.96%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
28.25% 28.56% 29.27% 28.50% 29.10% 29.40% 29.39% 29.71% 29.21% 29.02% 29.66%
Earnings before Interest and Taxes (EBIT)
270 234 218 219 213 199 180 187 182 188 145
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
349 312 297 292 283 269 247 259 246 251 207
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 4.49 0.00 0.00 0.00 4.03 0.00 0.00 0.00 4.48 0.00
Price to Tangible Book Value (P/TBV)
0.00 19.14 0.00 0.00 0.00 75.45 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.85 1.73 1.86 1.70 1.67 1.38 1.42 1.47 1.20 1.35 1.20
Price to Earnings (P/E)
20.58 20.38 22.98 21.58 21.91 18.86 18.88 21.45 19.69 21.66 16.26
Dividend Yield
0.63% 0.67% 0.62% 0.70% 0.73% 0.91% 0.90% 1.31% 1.36% 1.37% 1.97%
Earnings Yield
4.86% 4.91% 4.35% 4.63% 4.56% 5.30% 5.30% 4.66% 5.08% 4.62% 6.15%
Enterprise Value to Invested Capital (EV/IC)
2.93 2.36 2.90 2.70 2.67 2.00 2.40 2.46 2.16 1.98 2.01
Enterprise Value to Revenue (EV/Rev)
2.81 2.32 2.84 2.70 2.66 2.06 2.44 2.48 2.23 2.10 2.39
Enterprise Value to EBITDA (EV/EBITDA)
12.38 10.42 12.98 12.54 12.46 9.60 11.40 11.78 10.94 10.40 11.92
Enterprise Value to EBIT (EV/EBIT)
16.44 14.07 17.45 16.89 16.95 13.24 15.53 16.18 15.09 14.61 17.53
Enterprise Value to NOPAT (EV/NOPAT)
20.66 18.00 22.81 21.97 22.14 17.29 20.18 20.90 19.47 18.63 21.74
Enterprise Value to Operating Cash Flow (EV/OCF)
14.70 12.41 16.01 15.69 15.31 11.63 13.92 16.78 13.89 12.94 13.43
Enterprise Value to Free Cash Flow (EV/FCFF)
38.57 33.01 47.81 75.23 52.92 40.80 59.62 7.62 6.54 0.00 6.55
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.84 0.88 0.95 1.07 1.13 1.18 1.24 1.32 1.40 1.49 1.57
Long-Term Debt to Equity
0.79 0.83 0.86 1.06 1.12 1.17 1.23 1.31 1.39 1.47 1.56
Financial Leverage
0.91 0.98 1.01 1.11 1.18 1.30 1.33 1.22 1.29 1.05 1.41
Leverage Ratio
2.41 2.46 2.53 2.67 2.74 2.82 2.91 2.81 2.85 2.93 3.02
Compound Leverage Factor
2.13 2.11 2.13 2.27 2.30 2.34 2.34 2.28 2.29 2.35 2.24
Debt to Total Capital
45.70% 46.71% 48.60% 51.78% 52.98% 54.15% 55.38% 56.94% 58.33% 59.78% 61.10%
Short-Term Debt to Total Capital
2.56% 2.59% 4.39% 0.62% 0.50% 0.50% 0.49% 0.48% 0.55% 0.54% 0.58%
Long-Term Debt to Total Capital
43.13% 44.12% 44.21% 51.16% 52.48% 53.65% 54.89% 56.47% 57.78% 59.23% 60.52%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
54.30% 14.63% 51.40% 48.22% 47.02% 12.97% 44.62% 43.06% 41.67% 11.92% 38.90%
Common Equity to Total Capital
0.00% 38.66% 0.00% 0.00% 0.00% 32.89% 0.00% 0.00% 0.00% 28.31% 0.00%
Debt to EBITDA
1.98 2.09 2.26 2.49 2.56 2.63 2.71 2.82 3.03 3.15 3.71
Net Debt to EBITDA
1.88 1.99 2.09 2.32 2.40 2.53 2.57 2.66 2.90 3.09 3.57
Long-Term Debt to EBITDA
1.87 1.98 2.06 2.46 2.53 2.61 2.68 2.80 3.00 3.12 3.67
Debt to NOPAT
3.30 3.61 3.97 4.36 4.55 4.74 4.79 5.01 5.39 5.64 6.76
Net Debt to NOPAT
3.14 3.44 3.66 4.07 4.26 4.56 4.54 4.72 5.15 5.54 6.50
Long-Term Debt to NOPAT
3.12 3.41 3.61 4.31 4.50 4.70 4.75 4.96 5.34 5.59 6.69
Altman Z-Score
2.62 2.63 2.49 2.29 2.25 2.07 1.98 1.98 1.76 1.87 1.51
Noncontrolling Interest Sharing Ratio
100.00% 27.82% 100.00% 100.00% 100.00% 28.88% 100.00% 100.00% 100.00% 24.40% 100.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.06 1.05 1.04 1.35 1.37 1.28 1.27 1.26 1.29 1.25 1.21
Quick Ratio
0.84 0.81 0.81 1.07 1.11 1.04 0.99 0.99 1.01 0.97 0.93
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-127 -125 -171 -270 -184 -183 -233 1,091 1,148 -355 1,060
Operating Cash Flow to CapEx
176.95% 140.31% 181.56% 138.56% 171.31% 94.95% 143.75% 169.57% 228.36% 82.31% 46.95%
Free Cash Flow to Firm to Interest Expense
-4.00 -3.78 -4.86 -7.87 -5.21 -5.24 -6.50 30.04 31.53 -9.48 27.74
Operating Cash Flow to Interest Expense
9.08 8.40 7.59 6.34 6.78 5.76 5.99 5.69 6.26 4.59 1.84
Operating Cash Flow Less CapEx to Interest Expense
3.95 2.41 3.41 1.76 2.82 -0.31 1.82 2.34 3.52 -0.99 -2.07
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.86 0.85 0.84 0.83 0.83 0.82 0.82 0.71 0.70 0.70 0.61
Accounts Receivable Turnover
8.87 8.88 9.38 9.04 8.74 8.36 9.06 7.68 7.43 8.26 6.50
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.55 0.00 1.55 0.00 1.56 0.00 1.57 0.00 1.57 0.00 0.00
Accounts Payable Turnover
18.51 17.35 17.14 17.52 17.83 17.54 17.32 17.26 17.25 18.34 14.25
Days Sales Outstanding (DSO)
41.14 41.11 38.93 40.38 41.74 43.65 40.30 47.52 49.13 44.18 56.17
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
19.72 21.04 21.29 20.83 20.47 20.81 21.07 21.14 21.15 19.90 25.62
Cash Conversion Cycle (CCC)
21.42 20.07 17.63 19.55 21.28 22.84 19.22 26.38 27.98 24.28 30.55
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
5,287 5,263 5,104 5,065 4,939 4,948 4,765 4,623 4,592 4,618 4,389
Invested Capital Turnover
1.08 1.05 1.06 1.05 1.04 1.00 1.03 0.90 0.87 1.00 0.76
Increase / (Decrease) in Invested Capital
348 314 340 441 347 330 375 -947 -1,008 497 -941
Enterprise Value (EV)
15,469 12,444 14,812 13,687 13,194 9,898 11,445 11,355 9,932 9,134 8,831
Market Capitalization
10,183 9,287 9,707 8,623 8,255 6,640 6,680 6,732 5,340 5,869 4,443
Book Value per Share
$0.00 $20.52 $0.00 $0.00 $0.00 $16.44 $0.00 $0.00 $0.00 $13.13 $0.00
Tangible Book Value per Share
($15.67) $4.82 ($15.70) ($15.76) ($15.51) $0.88 ($15.54) ($15.45) ($15.62) ($2.36) ($15.36)
Total Capital
5,410 5,347 5,303 5,247 5,112 5,010 4,906 4,777 4,712 4,629 4,493
Total Debt
2,472 2,498 2,578 2,717 2,708 2,713 2,717 2,720 2,749 2,767 2,745
Total Long-Term Debt
2,333 2,359 2,345 2,684 2,683 2,688 2,693 2,698 2,723 2,742 2,719
Net Debt
2,349 2,375 2,379 2,535 2,536 2,608 2,575 2,566 2,629 2,714 2,641
Capital Expenditures (CapEx)
163 199 148 157 139 212 150 122 100 209 149
Debt-free, Cash-free Net Working Capital (DFCFNWC)
71 61 71 94 102 106 57 38 76 113 51
Debt-free Net Working Capital (DFNWC)
194 185 270 276 275 210 198 192 196 167 155
Net Working Capital (NWC)
55 46 37 244 250 185 175 169 170 141 129
Net Nonoperating Expense (NNE)
24 25 21 25 24 28 29 27 26 2.61 73
Net Nonoperating Obligations (NNO)
2,349 2,413 2,379 2,535 2,536 2,651 2,575 2,566 2,629 2,756 2,642
Total Depreciation and Amortization (D&A)
79 78 78 73 70 70 67 73 64 63 62
Debt-free, Cash-free Net Working Capital to Revenue
1.28% 1.14% 1.35% 1.85% 2.07% 2.21% 1.22% 0.83% 1.71% 2.60% 1.38%
Debt-free Net Working Capital to Revenue
3.51% 3.43% 5.17% 5.44% 5.55% 4.38% 4.23% 4.19% 4.40% 3.83% 4.20%
Net Working Capital to Revenue
1.00% 0.85% 0.70% 4.80% 5.03% 3.86% 3.72% 3.69% 3.81% 3.25% 3.49%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.50 $1.20 $1.08 $1.13 $1.12 $0.88 $0.85 $0.91 $0.88 $0.90 $0.45
Adjusted Weighted Average Basic Shares Outstanding
100.50M 99.90M 99.90M 99.90M 99.80M 99.50M 99.50M 99.50M 99.40M 99.20M 99.20M
Adjusted Diluted Earnings per Share
$1.48 $1.18 $1.06 $1.12 $1.10 $0.88 $0.84 $0.90 $0.87 $0.90 $0.45
Adjusted Weighted Average Diluted Shares Outstanding
102.10M 102.20M 102.10M 102M 102.20M 101.30M 101.40M 101.10M 100.90M 100.40M 100.50M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.88 $0.00 $0.00 $0.00 $0.90 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
100.80M 100.71M 100.75M 100.63M 100.69M 100.14M 100.24M 100.23M 100.24M 99.73M 99.79M
Normalized Net Operating Profit after Tax (NOPAT)
220 189 168 171 163 147 142 144 140 142 118
Normalized NOPAT Margin
15.15% 13.45% 12.45% 13.16% 12.38% 11.79% 11.76% 12.13% 12.03% 12.46% 10.85%
Pre Tax Income Margin
16.39% 14.33% 13.60% 14.29% 13.56% 13.22% 12.01% 12.74% 12.60% 13.27% 9.85%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
8.47 7.06 6.19 6.38 6.05 5.70 5.01 5.14 5.01 5.02 3.79
NOPAT to Interest Expense
6.93 5.69 4.76 4.99 4.63 4.21 3.95 3.97 3.84 3.78 3.10
EBIT Less CapEx to Interest Expense
3.35 1.08 2.01 1.81 2.09 -0.37 0.84 1.78 2.26 -0.56 -0.12
NOPAT Less CapEx to Interest Expense
1.80 -0.29 0.58 0.42 0.67 -1.85 -0.22 0.61 1.09 -1.80 -0.81
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
30.28% 31.48% 30.64% 32.54% 34.45% 37.82% 37.41% 44.17% 52.48% 53.46% 59.82%
Augmented Payout Ratio
39.94% 36.69% 30.64% 32.54% 34.45% 37.82% 37.41% 44.17% 52.48% 53.46% 59.82%

Frequently Asked Questions About Encompass Health's Financials

When does Encompass Health's financial year end?

According to the most recent income statement we have on file, Encompass Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Encompass Health's net income changed over the last 9 years?

Encompass Health's net income appears to be on an upward trend, with a most recent value of $596.60 million in 2024, rising from $183.10 million in 2015. The previous period was $463 million in 2023. See where experts think Encompass Health is headed by visiting Encompass Health's forecast page.

What is Encompass Health's operating income?
Encompass Health's total operating income in 2024 was $864.50 million, based on the following breakdown:
  • Total Gross Profit: $2.41 billion
  • Total Operating Expenses: $1.55 billion
How has Encompass Health revenue changed over the last 9 years?

Over the last 9 years, Encompass Health's total revenue changed from $3.16 billion in 2015 to $5.37 billion in 2024, a change of 69.9%.

How much debt does Encompass Health have?

Encompass Health's total liabilities were at $3.69 billion at the end of 2024, a 3.1% decrease from 2023, and a 0.5% decrease since 2015.

How much cash does Encompass Health have?

In the past 9 years, Encompass Health's cash and equivalents has ranged from $21.80 million in 2022 to $224 million in 2020, and is currently $85.40 million as of their latest financial filing in 2024.

How has Encompass Health's book value per share changed over the last 8 years?

Over the last 8 years, Encompass Health's book value per share changed from 6.69 in 2015 to 20.52 in 2024, a change of 206.8%.



This page (NYSE:EHC) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners